Stifel Financial
AUPH icon

Stifel Financial’s Aurinia Pharmaceuticals AUPH Stock Holding History

Stifel Financial’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.45M Buy
+165,401
New +$2.42M ﹤0.01% 1812
2024
Q3 		– Sell
-17,064
Closed -$97.4K – 3372
2024
Q2 		$97.4K Sell
17,064
-13,204
-44% -$69.5K ﹤0.01% 3217
2024
Q1 		$152K Sell
30,268
-324,455
-91% -$2.2M ﹤0.01% 3133
2023
Q4 		$3.19M Sell
354,723
-391
-0.1% -$3.22K ﹤0.01% 1359
2023
Q3 		$2.76M Sell
355,114
-10,907
-3% -$107K ﹤0.01% 1381
2023
Q2 		$3.54M Buy
366,021
+13,975
+4% +$145K ﹤0.01% 1254
2023
Q1 		$3.86M Buy
352,046
+27,463
+8% +$242K 0.01% 1170
2022
Q4 		$1.4M Sell
324,583
-643,348
-66% -$3.73M ﹤0.01% 1768
2022
Q3 		$7.28M Sell
967,931
-73,606
-7% -$637K 0.01% 764
2022
Q2 		$10.5M Sell
1,041,537
-375,416
-26% -$4.2M 0.02% 639
2022
Q1 		$17.5M Buy
1,416,953
+682,793
+93% +$10.6M 0.02% 543
2021
Q4 		$16.8M Buy
734,160
+54,290
+8% +$1.29M 0.02% 555
2021
Q3 		$15M Buy
679,870
+177,655
+35% +$2.82M 0.02% 570
2021
Q2 		$6.51M Buy
502,215
+104,206
+26% +$1.33M 0.01% 884
2021
Q1 		$5.17M Buy
398,009
+96,943
+32% +$1.41M 0.01% 944
2020
Q4 		$4.16M Buy
301,066
+152,638
+103% +$2.22M 0.01% 963
2020
Q3 		$2.19M Buy
148,428
+23,110
+18% +$335K ﹤0.01% 1165
2020
Q2 		$2.04M Buy
125,318
+63,476
+103% +$1.02M ﹤0.01% 1143
2020
Q1 		$894K Buy
61,842
+12,258
+25% +$216K ﹤0.01% 1506
2019
Q4 		$1M Buy
49,584
+6,573
+15% +$60.5K ﹤0.01% 1832
2019
Q3 		$231K Buy
43,011
+1,902
+5% +$11.5K ﹤0.01% 2576
2019
Q2 		$271K Sell
41,109
-5,411
-12% -$34.5K ﹤0.01% 2550
2019
Q1 		$303K Buy
46,520
+3,520
+8% +$23.4K ﹤0.01% 2351
2018
Q4 		$295K Sell
43,000
-2,196
-5% -$12.7K ﹤0.01% 2241
2018
Q3 		$300K Buy
45,196
+3,378
+8% +$18.9K ﹤0.01% 2360
2018
Q2 		$236K Buy
41,818
+20,100
+93% +$112K ﹤0.01% 2446
2018
Q1 		$113K Buy
21,718
+10,772
+98% +$57.6K ﹤0.01% 2555
2017
Q4 		$49K Buy
+10,946
New +$60.8K ﹤0.01% 2591

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Stifel Financial's AUPH Position: Q1 2026 in Review

Stifel Financial opened a new position in Aurinia Pharmaceuticals (AUPH) in Q1 2026: 165,401 shares worth $2.45M. The stake represents ﹤0.01% of the portfolio and ranks #1812 among its holdings. This is a return to the name: Stifel Financial previously reported a position in AUPH as recently as Q2 2024.

Stifel Financial first reported a position in AUPH in Q4 2017 and has held it in 28 quarters since. The position peaked at $17.5M in Q1 2022. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Stifel Financial held 165,401 shares of Aurinia Pharmaceuticals worth $2.45M as of Q1 2026.
  • Aurinia Pharmaceuticals was a new Stifel Financial position in Q1 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q1 2026, its #1812 holding.
  • Stifel Financial first reported a position in Aurinia Pharmaceuticals in Q4 2017 and has held it in 28 quarters since.
  • Stifel Financial's Aurinia Pharmaceuticals position peaked at $17.5M in Q1 2022.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.